KIR genotyping in 174 CML patients on first-line therapy with imatinib showed that the expression of KIR2DS1 was accompanied by a significantly lower 2-year probability to achieve cytogenetic response (Marin et al., 2012). Here, KIR3DL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.